Paradigm Shift

In Cancer Treatment

Learn More

Salarius is a cancer-focused biotechnology company developing treatments for patients who need them the most.

Our technology targets the epigenetic causes of cancer which is the study of the regulatory system that controls how genes are turned “on” or “off.” In certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which in some cases leads to cancer progression. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving disease. Our technology may also apply to hormonal cancers such as prostate, breast, ovarian cancer and perhaps other conditions like leukemia.

Salarius is the recipient of a 3-year $18.7 million Cancer Prevention and Research Institute of Texas (CPRIT) New Company Product Development award, is housed in the Jlabs@TMC facility in Houston, Texas and receives support from organizations like the National Pediatric Cancer Foundation.

News & Events

July 14, 2020


24 Hour Web Event: COVID19: Lessons Learned and the Path Forward

Salarius CEO David Arthur joins a panel of healthcare industry experts in a virtual discussion titled, “How to Work with the U.S. FDA When You Can’t Meet with Them.” Hosted by Pink Sheet reporter Derrick Gingery, the webinar highlights the best way to approach virtual meetings with the U.S. Food and Drug Administration, whether it’s a pre-IND call or a virtual advisory committee meeting. For more information on the webinar series, go to

Date and Time: July 21, 2020, 3pm ET

Registration for Webinar:




Webinar Link